Rgenix, operating under the name Inspirna, is a biotech startup that focuses on developing innovative treatments for common, previously untreatable cancers. The company's primary approach is to identify new drivers of cancer metastasis, which are the factors that cause cancer to spread within the body. They do this through their proprietary RNA-DRIVEr™ platform and microRNA mapping. The RNA-DRIVEr™ platform is a clinically-validated tool that helps to discover previously unknown factors that drive cancer growth and spread.

Inspirna's business model revolves around the development and commercialization of small molecules and biologics, which are types of drugs used in cancer treatment. The company's main clients are patients suffering from common cancers, particularly colorectal and non-small cell lung cancer.

Inspirna's revenue comes from the development and sale of these drugs. Currently, the company has two drugs in the pipeline. The first, ompenaclid (RGX-202), is in Phase 2 development for patients with RAS mutant colorectal cancer. The second, abequolixron (RGX-104), is in Phase 1b/2 development for patients with non-small cell lung cancer and endometrial cancer.

Inspirna's goal is to make cancer a manageable, chronic condition by providing more practical treatment options that prolong survival without decreasing patients’ quality of life. The company aims to develop medicines with oral dosing and safety profiles that can easily be incorporated into existing standard-of-care treatments.

Keywords: Biotech, Cancer Treatment, RNA-DRIVEr™ Platform, MicroRNA Mapping, Small Molecules, Biologics, Colorectal Cancer, Non-Small Cell Lung Cancer, Ompenaclid (RGX-202), Abequolixron (RGX-104).